Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

NCT01149720 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Tivantinib (ARQ 197) Capsule
DRUG: Tivantinib (ARQ 197) Tablet
DRUG: Tivantinib (ARQ 197) Capsule D, oral

Sponsor

Daiichi Sankyo

Collaborators

[object Object]
[object Object]